Nighthawk Biosciences

25/03/2022

Pleased to welcome Greg Burel, former Director of the Strategic National Stockpile (SNS), to Heat’s Biothreat Advisory Board. Read more on his appointment here: https://bit.ly/3umcO8d

03/02/2022

Heat Biologics is pleased to announce that the company will move its listing to the New York Stock Exchange American, where Heat expects to begin trading on Monday, February 14 under the same ticker symbol, HTBX. For details, see our announcement:

Heat Biologics a biopharmaceutical company that develops immunotherapies with the goal of  activating a patient's immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces…

31/01/2022

Join Bioprocess Online tomorrow, Tuesday Feb 1 at 11 a.m. ET, for a live interactive panel discussion with CEO Jeff Wolf and two other biotech execs to discuss pandemic preparedness. Register here:

Tuesday, February 01, 2022 at 11:00 AM Eastern Standard Time. Join Bioprocess Online Live for an interactive discussion on the role and value of public/private partnership in developing platforms for pandemic preparedness. We’ll explore the collaborations enabling agile response to public health e...

13/01/2022

Promising new preclinical data regarding PTX-35 has been accepted for publication in the American Journal of Transplantation and supports further study in inflammatory disease and in transplantation tolerance. PTX-35 is Heat's first antibody-based product, currently in a Phase 1 clinical trial for the treatment of patients with solid tumors. To learn more about the key findings surrounding the data, click here:

Heat Biologics a biopharmaceutical company that develops immunotherapies with the goal of  activating a patient's immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces…

21/12/2021

Heat is proud to deepen its commitment to biosecurity with the acquisition of Elusys Therapeutics and their approved countermeasure for inhalation in the event of accidental exposure or an intentional attack. Read our full announcement: https://bit.ly/3slfMu

08/12/2021

“RapidVax really presents a new paradigm in responding to biothreats,” said Heat CEO Jeff Wolf, in an interview with Homeland Preparedness News. Learn more about the RapidVax platform and how Heat is preparing to leverage it against both known and unknown emerging biological threats here:

Clinical stage biopharmaceutical company Heat Biologics, Inc. recently unveiled a new cellular vaccine platform that it says is designed to allow quicker manufacturing, greater stockpiling and customizability suited to combating a wide range of biological threats. The emergence of the … Read More ...

30/11/2021

Today, Heat Biologics unveiled its RapidVax® cellular vaccine platform at the 2021 World Antiviral Congress. RapidVax is being designed to enable an accelerated response to a wide variety of infectious agents by providing a flexible “plug-and-play” vaccine platform that can be stockpiled in advance, and then rapidly customized, manufactured, and deployed to address a specific emergent threat. For more details, click here: https://bit.ly/3G1pRzW

07/10/2021

We're pleased to welcome Paul Tebbey, Ph.D. as Senior Vice President of Product Development and Portfolio Strategy. Paul's experience in pharma & biotech includes several approved vaccines and therapies in immune-mediated disorders and infectious diseases. Read more:

Heat Biologics a biopharmaceutical company that develops immunotherapies with the goal of  activating a patient's immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces…

03/09/2021

David Lasseter, a member of our newly formed biothreat advisory board, spoke with Tom Temin on The Federal Drive podcast about the need to prepare the U.S. for biological threats and future pandemics, and Heat's ongoing efforts to do so. Listen here: https://bit.ly/2WLwaGY Federal News Network

If the government learned anything from the pandemic, it's that an outbreak from nature has much in common with a biological attack - at least in terms of preparedness and response. Federal Drive with Tom Temin asked David Lasseter, former deputy assistant secretary of Defense for Countering Weapons...

30/08/2021

Heat's new biothreat advisory board is actively focused on improving U.S. pandemic preparedness. Read more in BioSpace:

The CDC is taking a proactive stance and establishing a center that will use forecasting and outbreak analytics to guide public health decision-making.